Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Schibsted Tillväxtmedier in connection with its divestment of Prisjakt
Mandate

Vinge advises Schibsted Tillväxtmedier in connection with its divestment of Prisjakt

May 06, 2025 M&A Employment and Benefits Data protection and processing of personal data Intellectual Property Commercial Agreements

Schibsted Tillväxtmedier has entered into an agreement for the sale of Prisjakt to eEquity. The consideration is expected to amount to around SEK 500 million. Schibsted has owned Prisjakt for approximately 20 years and the divestment is made as part of Schibsted’s ongoing streamlining of its organisation and portfolio.

The transaction is expected to close in June 2025 and is conditional upon approval from the Swedish Competition Authority.

Vinge’s team consisted mainly of Johan Larsson, Johan Winnerblad and Gustav Wahlberg (M&A), Nicklas Thorgerzon (GDPR), Eva Fredrikson, Christoffer Nordin, Siri Blomberg and Carl Lexenberg (Kommersiella avtal), Alice Göransson (Commercial agreements) as well as Johan Gavelin (IP).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025